The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2021 | COVID-19: outcomes in multiple myeloma
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the impacts the COVID-19 pandemic has had on the management and treatment of multiple myeloma. An analysis of 650 patients with plasma cell disorders who were hospitalized with COVID-19 reported that age, high-risk disease status, renal disease and sub-optimal myeloma control were independent predictors of adverse outcomes with COVID-19 infection. Dr Munshi also discusses COVID-19 vaccination recommendations for patients with multiple myeloma. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
